Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2007

01-05-2007

Treatment Failure After Percutaneous Radiofrequency Ablation for Nonsurgical Candidates With Pulmonary Metastases From Colorectal Carcinoma

Authors: Tristan D. Yan, BSc (Med), MBBS, Julie King, MPH, Adrian Sjarif, BSc (Med), MBBS, Derek Glenn, MBBS, Karin Steinke, MD, Ahmed Al-Kindy, MD, David L. Morris, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2007

Login to get access

Abstract

Background

This study critically evaluated the local and overall treatment failure rates after percutaneous radiofrequency ablation (RFA) of pulmonary metastases from colorectal carcinoma.

Methods

Fifty-five nonsurgical candidates underwent RFA of colorectal pulmonary metastases. The primary end points of this study were local progression-free survival (PFS) and overall PFS. Univariate and multivariate analyses were performed to identify significant prognostic parameters for local and overall PFS.

Results

The local recurrence rate was 38%. For local PFS, univariate analysis demonstrated that the largest size of lung metastasis, the location of lung metastases, the post-RFA carcinoembryonic antigen level at 1 month, and the post-RFA carcinoembryonic antigen level at 3 months were significant prognostic indicators. In multivariate analysis, a largest size of lung metastasis of >3 cm and a post-RFA carcinoembryonic antigen level of >5 ng/mL at 1 month were independently associated with a reduced local PFS. The overall recurrence rate was 66%. For overall PFS, univariate analysis demonstrated that sex and the largest size of lung metastasis were significant prognostic indicators. In multivariate analysis, a largest size of lung metastasis of >3 cm was independently associated with a reduced overall PFS.

Conclusions

RFA of colorectal pulmonary metastases may have a useful role in local disease control for nonsurgical candidates, but its efficacy in patients with a lung metastasis of >3 cm is limited.
Literature
1.
Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analysis based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113:37–49CrossRef
2.
Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112:867–74PubMedCrossRef
3.
van Halteren HK, van Geel AN, Hart AA, et al. Pulmonary resection for metastases of colorectal origin. Chest 1995;107:1525–31
4.
Brister SJ, de Varennes B, Gordon PH, et al. Contemporary operative management of pulmonary metastases of colorectal origin. Dis Colon Rectum 1998; 31:786–92CrossRef
5.
Sakamoto T, Tsubota N, Iwanaga K, et al. Pulmonary resection for metastases from colorectal cancer. Chest 2001; 119:1069–72PubMedCrossRef
6.
Morrow CE, Vassilopoulos PP, Grage TB. Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer 1980; 45:2981–5PubMedCrossRef
7.
McCormack PM, Burt ME, Bains MS, et al. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992; 127:1403–6PubMed
8.
Rusch VW. Pulmonary metastasectomy. Current indications. Chest 1995; 107:322S–331SPubMed
9.
Watanabe I, Arai T, Ono M, et al. Prognostic factors in resection of pulmonary metastasis from colorectal cancer. Br J Surg 2003; 90:1436–40PubMedCrossRef
10.
Pfannschmidt J, Muley T, Hoffmann H, et al. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experienced in 167 patients. J Thorac Cardiovasc Surg 2003; 126:732–9PubMedCrossRef
11.
Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124:1007–13PubMedCrossRef
12.
Rena O, Casadio C, Viano F, et al. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 2002; 21:906–12PubMedCrossRef
13.
Colucci G, Gebbin V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23:4866–75PubMedCrossRef
14.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef
15.
Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059–69PubMedCrossRef
16.
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMed
17.
Douillard J-Y, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355:1041–7PubMedCrossRef
18.
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136–47PubMed
19.
Steinke K, Glenn D, King J, et al. Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol 2004; 11:207–12PubMedCrossRef
20.
King J, Glenn D, Clark W, et al. Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg 2004; 91:217–23PubMedCrossRef
21.
Steinke K, Sewell PE, Dupuy D, et al. Pulmonary radiofrequency ablation—an international study survey. Anticancer Res 2004; 24:339–43PubMed
22.
Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest 2006; 129:738–45PubMedCrossRef
23.
Lee J, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology 2004; 230:125–34PubMedCrossRef
24.
Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg 2005; 129:639–44PubMedCrossRef
25.
Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003; 125:929–37PubMedCrossRef
26.
Suh R, Reckamp K, Zeidler M, et al. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology 2005; 19:12–21PubMed
27.
Steinke K, Glenn D, King J, et al. Percutaneous pulmonary radiofrequency ablation: difficulty achieving complete ablations in big lung lesions. Br J Radiol 2003; 76:742–5PubMedCrossRef
28.
Ambrogi MC, Lucchi M, Dini P, et al. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg 2006; 30:177–83PubMedCrossRef
29.
Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004; 15:463–70PubMed
30.
Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. Acad Radiol 1995; 2:776–84PubMedCrossRef
31.
Dupuy DE, Mayo-Smith WW, DiPettrillo T, et al. Clinical experience of pulmonary radiofrequency ablation in 27 patients (abstract 389). Radiological Society of North America Proceedings, Chicago, November 2001
32.
Vaughn C, Mychaskiw G II, Sewell P. Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm. Anesth Analg 2002; 94:1149–51PubMedCrossRef
33.
Avital I, DeMatteo R. Combined resection of liver and lung metastases for colorectal cancer. Thorac Surg Clin 2006; 16:145–55PubMedCrossRef
Metadata
Title
Treatment Failure After Percutaneous Radiofrequency Ablation for Nonsurgical Candidates With Pulmonary Metastases From Colorectal Carcinoma
Authors
Tristan D. Yan, BSc (Med), MBBS
Julie King, MPH
Adrian Sjarif, BSc (Med), MBBS
Derek Glenn, MBBS
Karin Steinke, MD
Ahmed Al-Kindy, MD
David L. Morris, MD, PhD
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9271-x

Other articles of this Issue 5/2007

Annals of Surgical Oncology 5/2007 Go to the issue

Breast Oncology

A Phase II Trial of Image-Guided Radiofrequency Ablation of Small Invasive Breast Carcinomas: Use of Saline-Cooled Tip Electrode

OriginalPaper

Can Differences in Bowel Function After Surgery for Rectal Cancer Be Identified by the European Organization for Research and Treatment of Cancer Quality of Life Instrument?

Breast Oncology

Breast Cancer Sentinel Lymph Node Identification Rates: The Influence of Radiocolloid Mapping, Case Volume, and the Place of the Procedure

Editorial

Surgical Management of Familial Hyperparathyroidism

Editorial

Does (the) Form Follow Function?

Gastrointestinal Oncology

Analysis of Early Postoperative Morbidity Among Patients with Rectal Cancer Treated with and without Neoadjuvant Chemoradiotherapy